Literature DB >> 10969767

Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

S Hopkins-Donaldson1, J L Bodmer, K B Bourloud, C B Brognara, J Tschopp, N Gross.   

Abstract

Human neuroblastoma (NB) is a highly heterogeneous childhood cancer that is aggressively malignant or can undergo spontaneous regression that may involve apoptosis. NB-derived cell lines were tested for their sensitivity to apoptosis induced by the tumor-selective ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Noninvasive S-type cell lines (NB cell lines of substrate adherent phenotype) are highly sensitive to TRAIL, whereas invasive N-type cell lines (NB cell lines of neuronal phenotype) are resistant. Whereas both S- and N-type cell lines express TRAIL-R2, FADD, and caspase-3 and -10, only S-type cells express caspase-8. Reduced levels of caspase-8 protein were also observed in a malignant stage IV NB tumor when compared with a benign ganglioneuroma. The caspase-8 gene is not deleted in either N-type NB cell lines or high-stage NB tumors. Caspase-8 expression can be induced by demethylation with 5-aza-2'deoxycytidine, which enhances sensitivity to TRAIL. Therefore, caspase-8 expression is silenced in malignant NB, which correlates to tumor severity and resistance to TRAIL-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969767

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  71 in total

1.  Apoptotic DNA endonuclease (DNase-gamma) gene transfer induces cell death accompanying DNA fragmentation in human glioma cells.

Authors:  Ryuta Saito; Masaaki Mizuno; Toshihiro Kumabe; Takashi Yoshimoto; Sei-ichi Tanuma; Jun Yoshida
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

2.  Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study.

Authors:  Rani E George; Jill M Lahti; Peter C Adamson; Kejin Zhu; David Finkelstein; A Mark Ingle; Joel M Reid; Mark Krailo; Donna Neuberg; Susan M Blaney; Lisa Diller
Journal:  Pediatr Blood Cancer       Date:  2010-10       Impact factor: 3.167

Review 3.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

Review 4.  In search of tumor suppressing functions of menin.

Authors:  Yuqing Yang; Xianxin Hua
Journal:  Mol Cell Endocrinol       Date:  2007-01-11       Impact factor: 4.102

5.  PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.

Authors:  Kaiyu Yuan; Yong Sun; Tong Zhou; Jay McDonald; Yabing Chen
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

6.  Regulation of apoptosis and caspase-8 expression in neuroblastoma cells by isoforms of the IG20 gene.

Authors:  Liang Cheng Li; Jian Rong Sheng; Nirupama Mulherkar; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

7.  Caspase-mediated programmed cell death pathways as potential therapeutic targets in cancer.

Authors:  X Wen; Z-Q Lin; B Liu; Y-Q Wei
Journal:  Cell Prolif       Date:  2012-03-20       Impact factor: 6.831

8.  Menin-mediated caspase 8 expression in suppressing multiple endocrine neoplasia type 1.

Authors:  Ping La; Yuqing Yang; Satyajit K Karnik; Albert C Silva; Robert W Schnepp; Seung K Kim; Xianxin Hua
Journal:  J Biol Chem       Date:  2007-08-31       Impact factor: 5.157

9.  Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma.

Authors:  Kan Kondo; Seiji Yamasaki; Naoya Inoue; Tomoharu Sugie; Naoki Teratani; Takatsugu Kan; Yutaka Shimada
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

10.  Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells.

Authors:  Michael A Sheard; Shahab Asgharzadeh; Yin Liu; Tsen-Yin Lin; Hong-Wei Wu; Lingyun Ji; Susan Groshen; Dean A Lee; Robert C Seeger
Journal:  J Immunother       Date:  2013-06       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.